Avastin Injection, Solution
Product Images NDC 50242-061

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Avastin (NDC 50242-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Avastin 01)

A survival curve comparing the proportion of patients surviving over time in months between two groups: one treated with IFL plus placebo (red line) and the other treated with IFL plus Avastin (blue line). The graph includes the number of patients at risk at various time points for each group and shows a higher survival proportion for the group receiving IFL plus Avastin throughout the observed period up to 30 months.*

FDA Label Image

Figure 2 (Avastin 02)

A survival curve chart showing the proportion surviving versus study months. It compares two randomized treatment groups: 'Chemo' represented by a blue dashed line and 'Chemo + Avastin' represented by a red solid line. The chart includes sample sizes at risk over time for each group.*

FDA Label Image

Figure 3 (Avastin 03)

A Kaplan-Meier survival curve comparing the proportion of patients surviving over a duration of up to 50 months. Two groups are shown: PC (blue line) and PC plus Avastin (red line), with the red line generally indicating higher survival proportions. The chart includes numbers of patients at risk at various time points for both groups.*

FDA Label Image

Figure 4 (Avastin 04)

A Kaplan-Meier progression-free survival curve comparing Avastin (bevacizumab) plus IFN-alfa versus placebo plus IFN-alfa. The x-axis represents progression-free survival in months up to 24 months, while the y-axis shows the proportion progression-free. Patient counts at risk are provided for both groups at multiple time points.*

FDA Label Image

Figure 5 (Avastin 05)

A Kaplan-Meier survival curve chart depicting overall survival proportion over months for two groups: chemotherapy alone (red line) and chemotherapy plus bevacizumab (blue line). The chart includes risk numbers at various time points for each group, illustrating survival trends during a study period extending up to approximately 42 months.*

FDA Label Image

Figure 6 (Avastin 06)

A Kaplan-Meier plot depicting progression-free survival over months for three patient groups: CPP (blue line), CPB15 (red line), and CPB15+ (green line). The vertical axis shows proportion progression-free, while the horizontal axis represents time in months. Censored values are marked with crosses. A table below lists patient numbers at risk at different time points for each group.*

FDA Label Image

Figure 7 (Avastin 07)

A Kaplan-Meier survival curve chart showing progression-free survival over time in months. The x-axis represents the duration of progression-free survival (up to 24 months), and the y-axis shows the proportion of patients progression-free (from 0 to 1). Two groups are compared: CT (red line, n=182) and CT+BV (blue line, n=179). Tabulated numbers at risk for each group are displayed below the chart at various time points.*

FDA Label Image

Figure 8 (Avastin 08)

A Kaplan-Meier curve showing the proportion of patients progression-free over time in months since randomization. Two treatment groups are compared: CG+Pl (dashed line) and CG+Bv (solid line). The graph includes a legend, survival curves, and number of patients at risk at various time points, illustrating progression-free survival differences between treatments.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

A survival curve graph depicting the proportion of subjects surviving over study months for two treatment groups: Crb+Pac and Crb+Pac+Bev. The x-axis is labeled 'STUDY MONTH' and the y-axis 'Proportion Surviving.' The graph includes a risk table below the x-axis showing the number of patients at risk for each group over time.*

FDA Label Image

Avastin 09a

A Kaplan-Meier survival curve comparing the probability of overall survival over time (in months) between patients treated with Avastin plus atezolizumab and those treated with sorafenib. The graph includes the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Label for Avastin (bevacizumab) injection, 100 mg/4 mL (25 mg/mL) single-dose vial. The label indicates intravenous use, no preservative, and to discard unused portion. The labeler is Genentech, Inc., with NDC 50242-060-01, and it is marked Rx only.*

FDA Label Image

Avastin 11

Avastin 400 mg/16 mL (25 mg/mL) injection label for intravenous use. The label states it is a single-dose vial with no preservative and instructs to discard any unused portion. The product is a human prescription drug by Genentech, Inc., and the package size is 1 vial.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.